"Now that we know many of these women can safely avoid chemotherapy, we can spare them the physical and emotional effects that chemotherapy can have".
More specifically, in women over 50 years (whose risk of recurrence is lower), chemotherapy is useless for a score between 0 and 25.
Of the 9,719 eligible patients with follow-up information, 6,711 whose cancer recurrence risk was gauged "intermediate" in after-surgery tests were randomly assigned to receive hormone therapy alone or hormone therapy with adjuvant chemotherapy.
"Chemotherapy is an absolute cornerstone of breast cancer treatment, but with the side-effects being nearly unbearable for some we must ensure it is only given to those that will benefit from it".
Previously, the challenge doctors and patients faced was a mid-range score.
These women would instead be treated with radiation, surgery, and hormone therapy.
Nine-year survival rates were 93.9% without chemotherapy and 93.8% with chemotherapy, the study found.
"It confirms that using the 21-gene expression test on tumours, we can identify which women will benefit from endocrine (hormone) therapy only, thus eliminating the need for them to have chemotherapy".
A woman with terminal breast cancer has been cured completely.
British experts said the study was "exciting" even though it involved just one patient.
The breast cancer study focused on cases where chemo's value increasingly is in doubt: women with early-stage disease that has not spread to lymph nodes, is hormone-positive (meaning its growth is fueled by estrogen or progesterone) and is not the type that the drug Herceptin targets.More news: Key House races in California may be undecided for days
Women with scores of 10 or lower were considered not to need chemotherapy while those with scores 25 and over were considered to need it.
According to a research article "Epidemiology of breast cancer in Indian women" by Asia-Pacific Journal of Clinical Oncology, in India, breast cancer has been ranked number one cancer among Indian females.
"But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer".
The treatment, which succeeded after all other conventional treatments had failed, marks the first successful application of T-cell immunotherapy for late-stage breast cancer.
There are typically more than 55,000 new cases of breast cancer diagnosed in the United Kingdom each year, while around 11,500 people die from the disease. "I had a tumour in my chest I could feel shrinking", she said.
Researchers found skipping chemo won't hurt patients' chances of survival.
That's great news, since the short-term side-effects of chemotherapy can include everything from nausea, hair loss, fatigue and infection, to numbness in hands and feet, and other symptoms.
Because of her work as a nurse, she was familiar with chemotherapy's sometimes harsh effects.
Then they extracted immune cells from the tumour and grew billions of them, finding those which would be the most effective to kill her cancer.
Although this work does indicate that thousands of women can be spared this hard treatment, it doesn't mean skipping chemo is the right choice for all early-stage breast cancer patients. "Patients should not make any changes to their treatment based off this study, and should always consult their doctors".
Those with a recurrence score of up to 10 out of 100 have been shown not to benefit from chemo and those with a score of 26 or higher do benefit.